EP2408448A4 - Methods and compositions of treating a flaviviridae family viral infection - Google Patents

Methods and compositions of treating a flaviviridae family viral infection

Info

Publication number
EP2408448A4
EP2408448A4 EP10753957A EP10753957A EP2408448A4 EP 2408448 A4 EP2408448 A4 EP 2408448A4 EP 10753957 A EP10753957 A EP 10753957A EP 10753957 A EP10753957 A EP 10753957A EP 2408448 A4 EP2408448 A4 EP 2408448A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treating
methods
viral infection
flaviviridae family
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10753957A
Other languages
German (de)
French (fr)
Other versions
EP2408448A2 (en
Inventor
Ingrid C Choong
Jeffrey S Glenn
Wenjin Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Eiger Biopharmaceuticals Inc
Original Assignee
Leland Stanford Junior University
Eiger Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/383,071 external-priority patent/US9149463B2/en
Priority claimed from US12/383,030 external-priority patent/US9101628B2/en
Application filed by Leland Stanford Junior University, Eiger Biopharmaceuticals Inc filed Critical Leland Stanford Junior University
Publication of EP2408448A2 publication Critical patent/EP2408448A2/en
Publication of EP2408448A4 publication Critical patent/EP2408448A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP10753957A 2009-03-18 2010-03-16 Methods and compositions of treating a flaviviridae family viral infection Withdrawn EP2408448A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/383,071 US9149463B2 (en) 2007-09-18 2009-03-18 Methods and compositions of treating a Flaviviridae family viral infection
US12/383,030 US9101628B2 (en) 2007-09-18 2009-03-18 Methods and composition of treating a flaviviridae family viral infection
PCT/US2010/027405 WO2010107742A2 (en) 2009-03-18 2010-03-16 Methods and compositions of treating a flaviviridae family viral infection

Publications (2)

Publication Number Publication Date
EP2408448A2 EP2408448A2 (en) 2012-01-25
EP2408448A4 true EP2408448A4 (en) 2012-09-19

Family

ID=42740364

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10753957A Withdrawn EP2408448A4 (en) 2009-03-18 2010-03-16 Methods and compositions of treating a flaviviridae family viral infection

Country Status (4)

Country Link
EP (1) EP2408448A4 (en)
JP (1) JP2012520885A (en)
CN (1) CN102448457B (en)
WO (1) WO2010107742A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013009461A2 (en) * 2010-10-20 2016-07-12 Biota Scient Management vital polymerase inhibitors
EP3636264A1 (en) 2013-08-19 2020-04-15 The Regents of the University of California Compounds and methods for treating an epileptic disorder
WO2015051341A1 (en) 2013-10-03 2015-04-09 Araxes Pharma Llc Inhibitors of erk and methods of use
PT3261640T (en) 2015-02-25 2022-07-06 Univ California 5ht agonists for treating disorders
CN105884687B (en) * 2016-04-14 2018-06-22 梯尔希(南京)药物研发有限公司 A kind of preparation method of 5- benzyls benzydamine
CN114984030A (en) * 2022-06-23 2022-09-02 中国人民解放军海军军医大学 Application of ribavirin in preparation of tick-borne encephalitis virus resistant drugs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083472A1 (en) * 2000-04-28 2001-11-08 Acadia Pharmaceuticals, Inc. Muscarinic agonists
WO2002007761A1 (en) * 2000-07-20 2002-01-31 Merck & Co., Inc. Inhibiting hepatitis c virus processing and replication
DE102007028521A1 (en) * 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3428634A (en) * 1965-03-13 1969-02-18 Acraf 3-tertiary amino alkoxy-1-hydrocarbon indazoles
KR20060114022A (en) * 2004-02-27 2006-11-03 에프. 호프만-라 로슈 아게 Indazole derivatives and pharmaceutical compositions containing them
WO2006135383A2 (en) * 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles
JP5255559B2 (en) * 2006-03-31 2013-08-07 アボット・ラボラトリーズ Indazole compound
US8895598B2 (en) * 2007-09-18 2014-11-25 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083472A1 (en) * 2000-04-28 2001-11-08 Acadia Pharmaceuticals, Inc. Muscarinic agonists
WO2002007761A1 (en) * 2000-07-20 2002-01-31 Merck & Co., Inc. Inhibiting hepatitis c virus processing and replication
DE102007028521A1 (en) * 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS, REGISTRY,, 18 December 1984 (1984-12-18) - 22 December 2009 (2009-12-22), XP007920912 *
ANONYMOUS, REGISTRY,, 8 December 2008 (2008-12-08), XP007920913 *
ANONYMOUS, REGISTRY,, 8 November 2004 (2004-11-08), XP007920909 *
MANGANARO ET AL: "Activity of antiinflammatory steroidal and nonsteroidal compounds in some experimental infections. II. Activity of certain nonsteroidal antiinflammatory agents as compared with that of prednisone in murine hepatitis due to MHV3", INFLAMMATION, PLENUM PRESS, NEW YORK, NY, US, vol. Proc. Int. Symp, no. 1968, 1 January 1968 (1968-01-01), pages 67 - 71, XP008154270, ISSN: 0360-3997 *

Also Published As

Publication number Publication date
JP2012520885A (en) 2012-09-10
CN102448457B (en) 2015-09-02
WO2010107742A2 (en) 2010-09-23
WO2010107742A3 (en) 2011-03-10
EP2408448A2 (en) 2012-01-25
CN102448457A (en) 2012-05-09

Similar Documents

Publication Publication Date Title
EP2408449A4 (en) Methods and compositions of treating a flaviviridae family viral infection
EP2203168A4 (en) Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
EP2491033A4 (en) Azaindazoles to treat flaviviridae virus infection
AP3069A (en) Thienopyridine derivatives for the treatment and prvention of dengue virus infection
HK1223295A1 (en) Composition for treating hbv infection hbv
AP3409A (en) Inhibitors of flaviviridae viruses
ZA201109187B (en) Treatment and prevention of dengue virus infections
HK1170740A1 (en) Inhibitors of flaviviridae viruses
HK1152620A1 (en) Anti-viral compounds to treat hcv infection hcv
EP2493479A4 (en) Methods of treating viral associated diseases
EP2462152A4 (en) Composition and methods of treating viral infections and viral induced tumors
EP2483273A4 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
EP2521554A4 (en) Materials and methods for prevention and treatment of viral infections
EP2341924A4 (en) Methods of treating hepatitis c virus infection
EP2356236A4 (en) siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION
EP2534150A4 (en) Methods of treating viral infection
EP2408448A4 (en) Methods and compositions of treating a flaviviridae family viral infection
HK1165221A1 (en) Iminosugars and methods of treating viral diseases
EP2515652A4 (en) Compositions and methods for treatment of vitiligo
GB0908101D0 (en) Treatment of stress
EP2403507A4 (en) Treatment of infection
IL205035A0 (en) Methods of inhibiting viral infection
IL204940A0 (en) Methods of inhibiting viral infection
ZA201205639B (en) Compositions and methods for treating hepatitis b virus infection
GB0913944D0 (en) Treatment of diseases caused by viral infection

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111018

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120817

17Q First examination report despatched

Effective date: 20130611

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161001